R-Etodolac decreases β-catenin levels along with survival and proliferation of hepatoma cells

Journal of Hepatology

Volumn 46, Issue 5, 2007, Pages 849-857

  Behari, Jaideep ^a   Zeng, Gang ^a   Otruba, Wade ^a   Thompson, Michael D ^a   Muller, Peggy ^a   Micsenyi, Amanda ^a   Sekhon, Sandeep S ^b   Leoni, Lorenzo ^c   Monga, Satdarshan P S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c Salmedix Inc   (United States)

Author keywords

Catenin; Celecoxib; Cylooxygenase 2; Hepatocellular carcinoma; R Etodolac

Indexed keywords

BETA CATENIN; CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; GLUTAMATE AMMONIA LIGASE; NONSTEROID ANTIINFLAMMATORY AGENT; T CELL FACTOR PROTEIN; UVOMORULIN; WNT PROTEIN;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG ACTIVITY; DRUG MEGADOSE; ENANTIOMER; ENZYME INHIBITION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BETA CATENIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; ETODOLAC; GLYCOGEN SYNTHASE KINASE 3; GROWTH INHIBITORS; HUMANS; LIVER NEOPLASMS; PYRAZOLES; SULFONAMIDES; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 34047161489     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.11.017     Document Type: Article

References (42)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
2. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
3. Okuda K., Fujimoto I., Hanai A., and Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47 (1987) 4967-4972
4. Nhieu J.T., Renard C.A., Wei Y., Cherqui D., Zafrani E.S., and Buendia M.A. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155 (1999) 703-710
5. Ranganathan S., Tan X., and Monga S.P. beta-Catenin and met deregulation in childhood hepatoblastomas. Pediatr Dev Pathol 8 (2005) 435-447
6. Tan X., Apte U., Micsenyi A., et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 129 (2005) 285-302
7. Micsenyi A., Tan X., Sneddon T., Luo J.H., Michalopoulos G.K., and Monga S.P. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 126 (2004) 1134-1146
8. Monga S.P., Monga H.K., Tan X., Mule K., Pediaditakis P., and Michalopoulos G.K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 124 (2003) 202-216
9. Monga S.P., Pediaditakis P., Mule K., Stolz D.B., and Michalopoulos G.K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 33 (2001) 1098-1109
10. Sodhi D., Micsenyi A., Bowen W.C., Monga D.K., Talavera J.C., and Monga S.P. Morpholino oligonucleotide-triggered beta-catenin knockdown compromises normal liver regeneration. J Hepatol 43 (2005) 132-141
11. Miyoshi Y., Iwao K., Nagasawa Y., et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58 (1998) 2524-2527
12. Satoh S., Daigo Y., Furukawa Y., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24 (2000) 245-250
13. Merle P., de la Monte S., Kim M., et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127 (2004) 1110-1122
14. Koga H., Sakisaka S., Ohishi M., et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29 (1999) 688-696
15. Shiota G., Okubo M., Noumi T., et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46 (1999) 407-412
16. Kern M.A., Schubert D., Sahi D., et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36 (2002) 885-894
17. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
18. Appel G.B. COX-2 inhibitors and the kidney. Clin Exp Rheumatol 19 (2001) S37-S40
19. Brocks D.R., and Jamali F. The pharmacokinetics of etodolac enantiomers in the rat. Lack of pharmacokinetic interaction between enantiomers. Drug Metab Dispos 18 (1990) 471-475
20. Demerson C.A., Humber L.G., Abraham N.A., Schilling G., Martel R.R., and Pace-Asciak C. Resolution of etodolac and antiinflammatory and prostaglandin synthetase inhibiting properties of the enantiomers. J Med Chem 26 (1983) 1778-1780
21. Lu D., Zhao Y., Tawatao R., et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101 (2004) 3118-3123
22. Kolluri S.K., Corr M., James S.Y., et al. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 102 (2005) 2525-2530
23. Yasui H., Hideshima T., Hamasaki M., et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106 (2005) 706-712
24. Komoroski B.J., Zhang S., Cai H., et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32 (2004) 512-518
25. Zhang Z., Lai G.H., and Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39 (2004) 1028-1037
26. Liu C., Li Y., Semenov M., et al. Control of b-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108 (2002) 837-847
27. de La Coste A., Romagnolo B., Billuart P., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95 (1998) 8847-8851
28. Carruba G., Cervello M., Miceli M.D., et al. Truncated form of beta-catenin and reduced expression of wild-type catenins feature HepG2 human liver cancer cells. Ann N Y Acad Sci 886 (1999) 212-216
29. Pearl L.H., and Barford D. Regulation of protein kinases in insulin, growth factor and Wnt signaling. Curr Opin struct Biol 12 (2002) 761-767
30. Laurent-Puig P., Legoix P., Bluteau O., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120 (2001) 1763-1773
31. Thomas M.B., and Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23 (2005) 8093-8108
32. van de Wetering M., Oving I., Muncan V., et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4 (2003) 609-615
33. Clapper M.L., Coudry J., and Chang W.C. beta-catenin-mediated signaling: a molecular target for early chemopreventive intervention. Mutat Res 555 (2004) 97-105
34. Cheng A.S., Chan H.L., To K.F., et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 24 (2004) 853-860
35. Mayoral R., Fernandez-Martinez A., Bosca L., and Martin-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26 (2005) 753-761
36. Maier T.J., Janssen A., Schmidt R., Geisslinger G., and Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 19 (2005) 1353-1355
37. Lai G.H., Zhang Z., and Sirica A.E. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2 (2003) 265-271
38. Cervello M., Giannitrapani L., La Rosa M., et al. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med 13 (2004) 741-748
39. Li H., Liu L., David M.L., et al. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 64 (2002) 1325-1336
40. Gerhold D.L., Liu F., Jiang G., et al. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 143 (2002) 2106-2118
41. Liu J., and Farmer S.R. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279 (2004) 45020-45027
42. Hedvat M., Jain A., Carson D.A., et al. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell 5 (2004) 565-574